About BIOCYTOGEN-B Company

BioSeto is an international biotechnology company that drives the development of new drugs through innovative technology. It is committed to becoming the birthplace of new drugs around the world, with the mission of focusing on technological innovation, continuing the production of new drugs, and protecting human health. Based on the whole-human antibody RenmiceTM platform (renMAB and renLite mice) independently developed by Baiosetu and has completely independent intellectual property rights, organically integrates monoclonal and double antibody development technology platforms, an animal pharmacodynamic screening platform, and strong clinical development capabilities to form a unique new drug development capability covering the entire drug development process. Biosetu is developing large-scale drugs for more than 1,000 potential drug targets (the “Thousand Mouse AntiTM” program). With the implementation of the plan, BioSeto has signed 24 drug cooperative development agreements and reached licensing cooperation with 14 companies, including a number of MNCs, on the RenMice platform. The company has now established a pipeline of 12 core drug products, 2 of which are in phase II of international multi-center (MRCT) clinical trials and 2 in phase I of clinical trials. In the future, BioSeto will continue to work with global partners to continue to produce many antibody drugs to better benefit patients. Baiosetto is headquartered in Beijing and has branches in Haimen, Jiangsu, Shanghai, and Boston, USA.